Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom.

Bovine factor IX (Christmas factor) is a coagulation protein present in plasma in a precursor or inactive form. It is a glycoprotein (M, = 55,000) composed of a single polypeptide chain. Factor IX in the presence of calcium ions is converted to factor IX, by factor XI, (activated plasma thromboplastin antecedent) or a protease present in Russell’s viper venom. The activation of factor IX by the protease from Russell’s viper venom is due to the cleavage of a single internal Arg-Val peptide bond in factor IX. This leads to the formation of factor IX,,, a protein with the same molecular weight as the precursor. Factor IX,, is composed of two polypeptide chains held together by a disulfide bond(s), and these two chains have an NH,-terminal sequence of Tyr-Asn-Ser-Glyand Val-Val-Gly-Gly-. The mechanism of activation of factor IX catalyzed by the protease from Russell’s viper venom differs from that catalyzed by factor XI,. The latter enzyme activates factor IX in a two-step reaction. In the first step, an internal Arg-Ala bond is cleaved, and in the second step, an Arg-Val bond is cleaved. The second cleavage leads to the liberation of an activation peptide from the NH,-terminal portion of the heavy chain to produce factor IX,. The critical step in the activation of factor IX by both pathways is the cleavage of the same Arg-Val peptide bond and the formation of a new NH,-terminal sequence of Val-Val-Gly-Glyin the heavy chain of the enzyme which contains the active site serine residue. Factor I&w has approximately 50% of the specific activity of factor IX, in a coagulant or esterase assay, and both enzymes are inhibited by antithrombin III. A number of other purified plasma proteases were also examined for their ability to activate factor IX. Factor &,, (activated Stuart factor) catalyzed a slow but definite activation of factor IX, while the activation of factor IX by bovine kallikrein, thrombin, or factor XII, (activated Hageman factor) was negligible.

• Publication year

  1978

• Venue

  Journal of Biological Chemistry

• Publication date

  1978-03-25

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0021-9258(19)62334-3PMID 632245
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent developments in techniques for terminal and sequence studies in peptides and proteins.

  2006cited by this paper
• Characterization of bovine factor XIIa (activated Hageman factor).

  1977cited by this paper
• Serine proteases: structure and mechanism of catalysis.

  1977cited by this paper
• Activation of human factor X (Stuart factor) by a protease from Russell's viper venom.

  1977cited by this paper
• Activation of factor IX by thrombin preparations in the absence of factor XI.

  1976cited by this paper
• N-terminal amino acid sequences of variant-specific surface antigens from Trypanosoma brucei

  1976cited by this paper
• Inhibition of bovine factor IXa and factor Xabeta by antithrombin III.

  1976cited by this paper
• Proteolytic activation of protein C from bovine plasma.

  1976cited by this paper
• Characterization of human, bovine, and horse antithrombin III.

  1976cited by this paper
• Inhibition of human factor IXa by human antithrombin.

  1975cited by this paper
• A Simple Two‐step Isolation Procedure for Human and Bovine Antithrombin II/III (Heparin Cofactor): a Comparison of Two Methods

  1975cited by this paper
• The Activation of Human Factor IX

  1975cited by this paper
• Activation of factor IX by activated factor X: a link between the extrinsic and intrinsic coagulation systems

  1975cited by this paper
• The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent).

  1974cited by this paper
• Bovine factor IX (christmas factor). Further evidence of homology with factor X (Stuart factor) and prothrombin

  1974cited by this paper
• Isolation and characterization of bovine factor IX (Christmas factor).

  1973cited by this paper
• Application of sequenator analyses to the study of proteins.

  1972cited by this paper
• Bovine factor X 1 (Stuart factor). Mechanism of activation by protein from Russell's viper venom.

  1972cited by this paper
• Three-dimensional Structure of Tosyl-elastase

  1970cited by this paper
• Sensitive proteolytic enzyme assay using differential solubilities of radioactive substrates and products in biphasic systems.

  1970cited by this paper
• The chromatographic determination of cystine and cysteine residues in proteins as s-beta-(4-pyridylethyl)cysteine.

  1970cited by this paper
• Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads.

  1970cited by this paper
• Role of a Buried Acid Group in the Mechanism of Action of Chymotrypsin

  1969cited by this paper
• The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

  1969cited by this paper
• Separation from Russell's viper venom of one fraction reacting with factor X and another reacting with factor V.

  1969cited by this paper
• Structure of crystalline -chymotrypsin. II. A preliminary report including a hypothesis for the activation mechanism.

  1968cited by this paper
• Three-dimensional structure of tosyl-alpha-chymotrypsin.

  1967cited by this paper
• A protein sequenator.

  1967cited by this paper
• TITRATION BEHAVIOR OF BOVINE THROMBIN.

  1964cited by this paper
• PURIFICATION AND PROPERTIES OF BOVINE FACTOR X: MOLECULAR CHANGES DURING ACTIVATION.

  1964cited by this paper
• THE IDENTIFICATION AND SYNTHESIS OF ACTIVATED PLASMA THROMBOPLASTIN COMPONENT (PTC').

  1963cited by this paper
• The isolation and purification of a bovine-plasma protein which is a substrate for the coagulant fraction of Russell's-viper venom.

  1962cited by this paper
• The Coagulant Action of Russell's Viper Venom; The Use of Antivenom in Defining its Reaction with a Serum Factor

  1961cited by this paper
• [Differential characteristics of Hageman & P.T.A. factors; role of contact in the initial phase of coagulation].

  1958cited by this paper

• Blood coagulation factor IX: structural insights impacting hemophilia B therapy.

  2024cites this paper
• Russel Viper Venom

  2019cites this paper
• Reiber-Diagramm

  2019cites this paper
• Snake venom components in medicine: From the symbolic rod of Asclepius to tangible medical research and application.

  2018cites this paper
• Isolation and Characterization of Snake Venom Proteins and Peptides from Members of Viperidae and Elapidae Snake Families from Kilifi County

  2018cites this paper
• Structural Characterization of Factor VIII C2 Domain Activated Platelet Membrane Binding

  2017cites this paper
• Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.

  2015cites this paper
• Factor VIII assay mimicking in vivo coagulation conditions

  2014cites this paper
• low-density lipoprotein receptor Activation of factor IX zymogen results in exposure of a binding site for

  2013cites this paper
• Snake Venoms

  2012cites this paper
• Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium.

  2012cites this paper
• Venomous Snake Bites in Taiwan

  2012cites this paper
• Molecular genetic analysis of haemophilia A and B in several dog breeds

  2012cites this paper
• 1 Profiling of Mutations in the F 8 and F 9 , Causative Genes of Hemophilia A and Hemophilia B

  2012cites this paper
• A Sequential Mechanism for Exosite-mediated Factor IX Activation by Factor XIa*

  2012cites this paper
• Productive Recognition of Factor IX by Factor XIa Exosites Requires Disulfide Linkage between Heavy and Light Chains of Factor XIa*

  2011cites this paper
• Complex assemblies of factors IX and X regulate the initiation, maintenance, and shutdown of blood coagulation.

  2011cites this paper
• LDL receptor-related protein: Molecular analysis and identification of new ligands

  2011cites this paper
• UvA-DARE ( Digital Academic Repository ) LDL receptor-related protein : Molecular analysis and identification of new ligands

  2011cites this paper
• The Role of Factor XIa (FXIa) Catalytic Domain Exosite Residues in Substrate Catalysis and Inhibition by the Kunitz Protease Inhibitor Domain of Protease Nexin 2*

  2011cites this paper
• Coagulation procofactor activation by factor XIa

  2010cites this paper
• Use of a Bacterially Expressed Human Factor IX Light Chain to Develop Polyclonal Antibody Anti-hFIX

  2009cites this paper
• Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa.

  2009cites this paper
• Activation mechanisms of coagulation factor IX

  2009cites this paper
• Characterization of Novel Forms of Coagulation Factor XIa

  2008cites this paper
• Identification of mutations in the F9 gene including exon deletion by multiplex ligation‐dependent probe amplification in 33 unrelated Korean patients with haemophilia B

  2008cites this paper
• Factor XI Homodimer Structure Is Essential for Normal Proteolytic Activation by Factor XIIa, Thrombin, and Factor XIa*

  2008cites this paper
• New insights into the functions and N‐glycan structures of factor X activator from Russell’s viper venom

  2008cites this paper
• Isolation and characterization of "Reprotoxin", a novel protein complex from Daboia russelii snake venom.

  2008cites this paper
• Functional Analysis of the Factor IX Epidermal Growth Factor-Like Domain Mutation Ile66Thr Associated with Mild Hemophilia B

  2007cites this paper
• Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation.

  2007cites this paper
• Expression, purification and characterization of factor IX derivatives using a novel vector system.

  2006cites this paper
• Antivenom treatment and renal dysfunction in Russell's viper snakebite in Taiwan: a case series.

  2006cites this paper
• Characterization of a Monoclonal Antibody B1 That Recognizes Phosphorylated Ser-158 in the Activation Peptide Region of Human Coagulation Factor IX*

  2006cites this paper
• The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.

  2006cites this paper
• The influence of sodium ion binding on factor IXa activity

  2006cites this paper
• Shedaoenase, a novel fibrinogenase from the venom of Agkistrodon shedaoenthesis Zhao.

  2005cites this paper
• Exosite-mediated Substrate Recognition of Factor IX by Factor XIa

  2005cites this paper
• Snake venoms and hemostasis

  2005cites this paper
• Purification, identification, and characterization of elastase on erythrocyte membrane as factor IX-activating enzyme.

  2004cites this paper
• Contribution of Basic Residues of the Autolysis Loop to the Substrate and Inhibitor Specificity of Factor IXa*

  2003cites this paper
• The Factor IX γ-Carboxyglutamic Acid (Gla) Domain Is Involved in Interactions between Factor IX and Factor XIa*

  2003cites this paper
• Physiological fIXa Activation Involves a Cooperative Conformational Rearrangement of the 99-Loop*

  2003cites this paper
• Functional analysis of the EGF‐like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B

  2003cites this paper
• Functional analysis of the EGF-like domain mutations Pro 55 Ser and Pro 55 Leu , which cause mild hemophilia

  2003cites this paper
• Identification of Functionally Important Residues of the Epidermal Growth Factor-2 Domain of Factor IX by Alanine-scanning Mutagenesis

  2002cites this paper
• Localization of the Heparin Binding Exosite of Factor IXa*

  2002cites this paper
• The Connecting Segment between Both Epidermal Growth Factor-like Domains in Blood Coagulation Factor IX Contributes to Stimulation by Factor VIIIa and Its Isolated A2 Domain*

  2002cites this paper
• The N-terminal Epidermal Growth Factor-like Domain of Coagulation Factor IX

  2002cites this paper
• Residues 88–109 of Factor IXa Are Important for Assembly of the Factor X Activating Complex*

  2002cites this paper
• Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X

  2002cites this paper
• The Interaction of Factor XIa with Activated Platelets but Not Endothelial Cells Promotes the Activation of Factor IX in the Consolidation Phase of Blood Coagulation*

  2002cites this paper
• Russell's viper snakebite in Taiwan: differences from other Asian countries.

  2002cites this paper
• An anti-EGF monoclonal antibody that detects intramolecular communication in factor IX.

  2001cites this paper
• Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis.

  2001cites this paper
• Hydrophobic Contact between the Two Epidermal Growth Factor-like Domains of Blood Coagulation Factor IX Contributes to Enzymatic Activity*

  2000cites this paper
• Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.

  2000cites this paper
• Activation of factor IX by factor XIa.

  2000cites this paper
• Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding.

  1999cites this paper
• HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Factor XI Messenger RNA in Human Platelets

  1999cites this paper
• Snake venoms and the hemostatic system.

  1998cites this paper
• Factor IX activation by factor XIa proceeds without release of a free intermediate.

  1997cites this paper
• Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants

  1997cites this paper
• Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols

  1997cites this paper
• A binding site expressed on the surface of activated human platelets is shared by factor X and prothrombin.

  1996cites this paper
• Factor XIa Induced Activation of the Intrinsic Cascade In Vivo

  1996cites this paper
• Ca2+ Binding to the First Epidermal Growth Factor-like Domain of Human Blood Coagulation Factor IX Promotes Enzyme Activity and Factor VIII Light Chain Binding*

  1996cites this paper
• Blood, Plasma Proteins, Coagulation, Fibrinolysis, and Thrombocyte Function

  1996cites this paper
• Kinetics of human factor VII activation.

  1996cites this paper
• Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme (*)

  1995cites this paper
• Regulation of the Tertiary Structure and Function of Coagulation Factor IX by Magnesium(II) Ions (*)

  1995cites this paper
• Inventory of exogenous hemostatic factors affecting the prothrombin activating pathways. For the Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

  1994cites this paper
• Protein engineering of the hydrophobic domain of human factor IX.

  1994cites this paper
• Action of snake venom components on the haemostatic system.

  1993cites this paper
• Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.

  1993cites this paper
• Domain structure and domain-domain interactions in human coagulation factor IX.

  1993cites this paper
• The role of the membrane in the expression of the vitamin K-dependent enzymes.

  1992cites this paper
• The evaluation of complex-dependent alterations in human factor VIIa.

  1992cites this paper
• Aminonaphthalenesulfonamides, a new class of modifiable fluorescent detecting groups and their use in substrates for serine protease enzymes.

  1992cites this paper
• Heparin therapy in Russell's viper bite victims with disseminated intravascular coagulation: a controlled trial.

  1992cites this paper
• Components and Assembly of the Factor X Activating Complex

  1992cites this paper
• Surface-dependent hemostasis.

  1992cites this paper
• Molecular defects of Factor IX

  1991cites this paper
• The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region.

  1991cites this paper
• Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.

  1991cites this paper
• gamma-Carboxyglutamic acid (Gla)-domainless blood coagulation factor IXa species: preparation and properties.

  1991cites this paper
• Effects of snake venom proteins on blood platelets.

  1990cites this paper
• Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels.

  1990cites this paper
• Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.

  1990cites this paper
• Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase.

  1989cites this paper
• Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.

  1989cites this paper
• Factor IX Kawachinagano: impaired function of the Gla‐domain caused by attached propeptide region due to substitution of arginine by glutamine at position −4

  1989cites this paper
• Snake Envenomation Incidence, Clinical Presentation and Management

  1989cites this paper
• The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences.

  1988cites this paper
• Circular dichroism analysis of the secondary structures of bovine blood coagulation factor IX, factor X, and prothrombin

  1988cites this paper
• Transfusion-induced specific anti-factor XI inhibitor in a patient with previously unrecognized factor XI deficiency.

  1988cites this paper
• Haemostatic disturbances in patients bitten by Russell's viper (Vipera russelli siamensis) in Burma

  1988cites this paper
• Biochemical and Functional Properties of Factor XI and Prekallikrein

  1987cites this paper
• The molecular genetics of hemophilia B.

  1987cites this paper
• Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.

  1986cites this paper